Phase 2 Psoriatic Arthritis Trial, Recruiting (NCT07315061)

Phase 2 Psoriatic Arthritis Trial, Recruiting NCT07315061 Sponsor: InventisBio Co., Ltd Condition: Psoriatic Arthritis

Printed from Voxsanity (voxsanity.com.au) — NCT07315061 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriatic Arthritis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing to take part voluntarily, have been fully informed about the study, and agree to follow the study procedures by signing a consent form
People who are male or female, aged between 18 and 70 years old at the time of signing the consent form
People who have had psoriatic arthritis (a condition causing joint inflammation linked to psoriasis) for at least 3 months before signing the consent form
People who currently have active joint problems, including at least 3 joints that are tender when touched and at least 3 joints that are visibly swollen

Who may not be able to join:

People with a history of certain infections, as defined by the trial's specific guidelines (confirm with trial site)
People who have certain medical conditions or disorders listed in the trial's guidelines (confirm with trial site)
People who have a serious, uncontrolled, or unstable health condition affecting any organ in the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: yi liu, phD, West China School of Medicine

Phone: 13401466347

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07315061

Sponsor: InventisBio Co., Ltd

Phase: Phase 2

Status: Recruiting

Condition: Psoriatic Arthritis

Trial contact: 13401466347

More information: https://clinicaltrials.gov/study/NCT07315061

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing to take part voluntarily, have been fully informed about the study, and agree to follow the study procedures by signing a consent form
People who are male or female, aged between 18 and 70 years old at the time of signing the consent form
People who have had psoriatic arthritis (a condition causing joint inflammation linked to psoriasis) for at least 3 months before signing the consent form
People who currently have active joint problems, including at least 3 joints that are tender when touched and at least 3 joints that are visibly swollen

Who may not be able to join:

People with a history of certain infections, as defined by the trial's specific guidelines (confirm with trial site)
People who have certain medical conditions or disorders listed in the trial's guidelines (confirm with trial site)
People who have a serious, uncontrolled, or unstable health condition affecting any organ in the body

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

InventisBio Co., Ltd

Registry

ClinicalTrials.gov

Start date

16 January 2026

Est. completion

15 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of subjects achieving ACR20 at Week 12 of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov